Research Article

Fluticasone furoate/Vilanterol 92/22 μg once-a-day vs Beclomethasone dipropionate/Formoterol 100/6 μg b.i.d. in asthma patients: a 12-week pilot study

Claudio Terzano* and Francesca Oriolo

Published: 27 September, 2017 | Volume 1 - Issue 1 | Pages: 013-022

Two of the most recent LABA/ICS combinations for treatment of persistent asthma are Fluticasone furoate/Vilanterol 92/22 µg (Ellipta) and Beclomethasone dipropionate/Formoterol 100/6 µg (Nexthaler).

Objective: To compare once-daily Fluticasone/ Vilanterol combination with twice daily Beclomethasone/ Formoterol association in moderate asthma, in terms of quality of life and lung function.

Methods: Fourty patients with moderate asthma treated with Beclomethasone/Formoterol 100/6 µg or Fluticasone/Vilanterol 92/22 µg. We revalued patients in terms of lung function and Asthma Control Test, at 4, 8 and 12 weeks to assess any differences between the two groups. After 4 weeks, thirty-one of the fourty patients were evaluated in terms of respiratory function at predetermined time intervals.

Result: In patients treated with beclomethasone/formoterol FEV1 presented a mean value of 78% at the third visit and of 79.1% during the final check, compared with 74.5% and to 75.8% in patients in treatment with fluticasone/vilanterol (p 0.01). Mean values of IC and MMEF25-75% were higher in patients treated with beclomethasone/formoterol compared with fluticasone/vilanterol. For the dyspnea it was a difference at the third observation. For the nocturnal symptoms and the use of rescue drug there was a significant difference, except at the beginning. For the perception of control by patients, there was a difference in the two groups at the beginning, after 4 and 8 weeks. Total ACT score showed a significant difference after 4, 8 and 12 weeks. In the group treated with beclomethasone/formoterol FEV1 value was significantly higher at a distance of four hours after drug administration (p 0.04) and after the second dose (p 0.02) compared with the group treated with fluticasone/vilanterol.

Discussion: Patients in treatment with beclomethasone/formoterol showed improved asthma control and nocturnal symptoms and more stable respiratory function compared with patients receiving fluticasone/vilanterol.

Read Full Article HTML DOI: 10.29328/journal.jprr.1001004 Cite this Article Read Full Article PDF


Asthma; Asthma control test; ICS/LABA


  1. Sidebotham HJ, Roche WR. Asthma deaths; persistent and preventable mortality. Histopatology 2003; 43:105-117. Ref.: https://goo.gl/5E5DFj
  2. Levy ML The national review of asthma deaths: what did we learn and what needs to change? Breathe (Sheff). 2015; 11: 14-24. Ref.: https://goo.gl/NMjWs6
  3. Bateman ED, Boushey HA, Bousquet J, Busse WW, Clark TJ, et al. Can guideline-defined asthma control be achieved?The Gaining Optimal Asthma Control Study. Am J Respir Crit Care Med. 2004; 170: 836-844. Ref.: https://goo.gl/VfuBqc
  4. Antonicelli L, Bucca C, Neri M, Sabbatani P, Bonifazi F, et al. Asthma severity and medical resource utilization. Eur Respir J. 2004; 23: 723-729. Ref.: https://goo.gl/L8PNF9
  5. King ME, Mannino DM, Holgin F. Risk factors for asthma incidence. A review of recent prospective evidence. Panminerva Med. 2004; 46: 97-110. Ref.: https://goo.gl/HffCfM
  6. Barnes PJ, Chung KF, Page CP. Inflammatory Mediators of Asthma: An Update Pharmacol Rev. 1998; 50: 515-596. Ref.: https://goo.gl/Y35jQi
  7. Barnes PJ. Cytokine modulators as novel therapies for airway disease Eur Respir J suppl. 2001; 34: 67-77. Ref.: https://goo.gl/LWU7rj
  8. Allegra L, Cremonesi G, Girbino G, Ingrassia E, Nicolini G, et al. Real-life prospective study on asthma control in Italy: cross-sectional phase results Respir Med. 2012; 106: 205-214. Ref.: https://goo.gl/HoS5RJ
  9. Terzano C, Cremonesi G, Girbino G, et al. 1-year prospective real life monitoring of asthma control and quality of life in Italy Respir Res. 2012; 6: 13-112. Ref.: https://goo.gl/j9nH2W
  10. Sterling R, Lim J, Frith L, et al. Efficacy and optimal dosing interval of the long-acting beta2 agonist, vilanterol, in persistent asthma: a randomized trial. Respir Med. 2012; 106: 1110-1115. Ref.: https://goo.gl/D5hnHd
  11. Bateman ED, Bleecker ER, Lotvall J, Woodcock A, Medley H, et al. Dose effect of once-daily fluticasone furoate in persistent asthma: a randomized trial. Respir Med. 2012; 106: 642-650. Ref.: https://goo.gl/ehb1SX
  12. Global initiative for Asthma (GINA). Global Strategy for Asthma Management and Prevention. Report. 2014.
  13. Desai D, Brightling C. Cough due to asthma, cough-variant asthma and non -asthmatic eosinophilic bronchitis. Otoryngol Clin North Am. 2010; 43: 123-130. Ref.: https://goo.gl/yJRZ1t
  14. Kamimura M, Izumi S, Hamamoto Y, Morita A, Toyota E, et al. Superiority of nebulized corticosteroids over dry powder inhalers in certain patients with cough variant asthma or cough-predominant asthma. Allergol Int. 2012; 61: 411-417. Ref.: https://goo.gl/4BXXmG
  15. Colombo G, Terzano C, Colombo P, Petroianni A, Ricci A, et al. Methacholine dry powder inhaler as a new tool for bronchial challenge test. Int J Pharm. 2008; 352:165-171. Ref.: https://goo.gl/LxyKCa
  16. Nathan RA, Sorkness CA, Kosinsky M, Schatz M, James MS, et al. Development of the Asthma Contro Test: a survey for assessing asthma control. J allergy Clin Immunol. 2004; 113: 59-65. Ref.: https://goo.gl/Qsts7D
  17. Bateman ED, Boushey HA, Bousquet J, William W, Tim JM et al. The Gaining Optimal Asthma control Study American Journal Respiratory Critical Care Medicine. 2004; 170: 836-844. Ref.: https://goo.gl/VRXcKb
  18. Connor BJ, Collarini S, Poli G, Brindicci C, Spinola M, et al. Rapid effects of extrafine beclomethasone dipropionate/formoterol fixed combination inhaler on airway inflammation and bronchoconstriction in asthma: a randomised controlled trial. Pulm Med. 2011; 21: 11-60. Ref.: https://goo.gl/VzhPvx
  19. Corradi M, Pigeon-Francisco C, Baronio R, Petruzzelli S, Klaus F, et al. Beclometasone-formoterol as maintenance and reliever treatment in patients with asthma: a double-blind, randomised controlled trial. Lancet Respir Med. 2013; 1: 23-31. Ref.: https://goo.gl/hVg1zr
  20. Gerzeli S, Rognoni C, Quaglini S, Cavallo MC, Papi A, et al. Cost-effectiveness and cost-utility of beclomethasone/formoterol versus fluticasone propionate/salmeterol in patients with moderate to severe asthma. Clin Drug Investig. 2012; 32: 253-265. Ref.: https://goo.gl/thdirG
  21. Paggiaro P, Patel S, Nicolini G, Pradelli L, Zaniolo O, et al. Stepping down from high dose fluticasone/salmeterol to extrafine BDP/F in asthma is cost-effective. Respir Med. 2013; 107: 1531-1537. Ref.: https://goo.gl/NMvmuq
  22. Price D, Small I, Haughney J, Ryan D, Gruffydd-Jones K, et al. Clinical and cost effectiveness of switching asthma patients from fluticasone-salmeterol to extra-fine particle beclometasone-formoterol: a retrospective matched observational study of real-world patients. Prim Care Respir J. 2013; 22: 439-448. Ref.: https://goo.gl/BK3CzQ
  23. Kew KM, Karner C, Mindus SM, Ferrara G. Combination formoterol and budesonide as maintenance and reliever therapy versus combination inhaler maintenance for chronic asthma in adults and children. Cochrane Database Syst Rev. 2013; 16. Ref.: https://goo.gl/pbNG8R
  24. Bruce SA, Scherer YK. Maintenance and symptom relief with budesonide plus formoterol reduced severe asthma exacerbations. Evidence-Based Nursing 2005; 8: 78. Ref.: https://goo.gl/C4g4Ri
  25. Byrne PM, Bisgaard H, Godard PP, Pistolesi M, Palmqvist M, et al. Budesonide/formoterol combination therapy as both maintenance and reliever medication in asthma. American Journal of Respiratory and Critical Care Medicine 2005; 171: 129-136. Ref.: https://goo.gl/Tr2JpD
  26. Byrne PM, Godard P, Pistolesi M, et al. Single inhaler therapy with budesonide/formoterol improves asthma control compared with fixed dosing with budesonide/formoterol or a higher dose of budesonide alone [Abstract]. American Thoracic Society 100th International Conference. 2004; 21-26.
  27. Kempsford RD, Oliver A, Bal J, Tombs L, Quinn D, et al. The efficacy of once-daily fluticasone furoate/vilanterol in asthma is comparable with morning or evening dosing. Respir Med. 2013; 107: 1873-1880. Ref.: https://goo.gl/RUxz1S
  28. Woodcock A, Bleecker ER, Lotvall J, O'Byrne PM, Bateman ED, et al. Efficacy and safety of fluticasone furoate/vilanterol compared with fluticasone propionate/salmeterol combination in adult and adolescent patients with persistent asthma: a randomized trial. Chest. 2013; 144: 1222-1229. Ref.: https://goo.gl/5tyvnP
  29. Byrne PM, Bleecker ER, Bateman ED, et al. Once-daily fluticasone furoate alone or combined with vilanterol in persistent asthma. Eur Respir J. 2014; 43: 773-782. Ref.: https://goo.gl/dLCZHN
  30. Popov TA, Petrova D, Kralimarkova TZ, Ivanov Y, Popova T, et al. Real life clinical study design supportino the effectiveness of extra-fine inhaled beclomethasone/formoterol at the level of small airways of asthmatics. Pulm Pharmacol Ther. 2013; 14: 624-629. Ref.: https://goo.gl/SNGMu2


Figure 1

Figure 1

Figure 1

Figure 2

Figure 1

Figure 3

Figure 1

Figure 4

Figure 1

Figure 5

Figure 1

Figure 6

Figure 1

Figure 7

Figure 1

Figure 8

Figure 1

Figure 9

Similar Articles

Recently Viewed

Read More

Most Viewed

Read More

Help ?